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Continuous renal replacement therapy (CRRT) has received
increasing attention in recent years parallel to the publication of
several favourable data regarding the use of this technique in different
clinical conditions such as congestive heart failure (CHF) [1,2] and
contrast induced nephropathy (CIN) [3,4]. Moreover, the improve-
ment in technology has led to the diffusion of devices easier to use,
that can be managed in Cardiology Units also out of the intensive care
setting, overcoming logistic and practical problems.
CRRT can be performed in cardiac patients with three different
main techniques:
a) Slow Continuous Ultrafiltration (SCUF): removes plasma water
thank to a transmembrane pressure gradient (diffusion); solutes
are passively removed accompanying the plasma water flow
(convection);
b) Continuous Veno-Venous Hemofiltration (CVVHF): removes solutes
bymeans of convection but fluid loss determined by ultrafiltration is
compensated by a reinfusion solution;
c) Continuous Veno-Venous Hemo-Diafiltration (CVVHDF): removes
liquids and solutes with the implementation of both dialysis and
hemofiltration.
From January 2005 to December 2010 132 patients were consecu-
tively treated with CRRT in the Cardiac Step Down Unit (CSDU) of the
University of Florence, consisting of eight monitored beds with a
nurse/patients ratio of 1:4. In the present letter we report our
experience with CRRT and, in particular, in-hospital outcomes of
patients submitted to this procedure and data regarding safety of CRRT
in a non-intensive environment.
Themain indications to CRRT in our populationwere: decompensated
CHF in 63patients (47.7%), prevention or treatment of CIN in 42patients
(31.8%) and acute kidney injury (AKI) for several causes in 27 critical
cardiac patients (20.5%).
CHF patients were treated with CRRT if they showed at admission
signs of fluid overloadwith peripheral edema N2+ and at least one of
the following: 1) pulmonary rales or crackling; 2) dyspnea; 3) third
heart sound; 4) jugular venous distension; 5) positive epato-jugular
reflux; 6)maximal systolic arterial pulmonary pressure above 50 mm
Hg at echocardiogram; 7) radiographic pleural effusion. A clinical
score was used to objectivate the severity of clinical status of our
patients assigning one point for each sign or symptom mentioned
above (minimum value 2, maximum 8). CHF patients submitted to
CRRT were those unresponsive to diuretic therapy despite the
increased doses. They were divided in two subgroups: a) those
with serum creatinine N3 mg/dl or glomerular filtration rate (GFR)
MDRD b30 ml/min/m2 were treated with CVVHDF; b) those with
serum creatinine b3 mg/dl or GFRMDRDbetween 30 and 60 ml/min/m2
treated with SCUF. Diuretic therapy was withdrawn during CRRT.
CIN was defined as an absolute increase in serum creatinine
≥0.5 mg/dl from baseline or as a relative increase≥25% from baseline
within 48–72 hours after contrast medium administration after the
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Table 1
Clinical and biohumoral parameters variations, modality of CRRT and its related
complications in congestive heart failure patients.
Congestive heart failure patients, n=63 (47.6%)
Demographic features
Age, years (mean±SD) 71.6±13.6
Male gender, n (%) 43 (68.2)
Hypertension, n (%) 33 (52.4)
Diabetes mellitus, n (%) 30 (47.5)
Dyslipidemia, n (%) 20 (15.1)
Chronic kidney injury, n (%) 37 (58.7)
Ischemic cardiomyopathy, n (%) 33 (25.0)
Primitive cardiomyopathy, n (%) 22 (16.7)
Valvulopathy, n (%) 8 (6.1)
Ejection fraction pre-CRRT (mean±SD) 31.5±14.9
In-hospital mortality, n (%) 8 (7.9)
Modality of CRRT
SCUF, n (%) 33 (52.4)
CVVHDF, n (%) 30 (47.6)
Treatment length, hours [median (IR)] 48 (72–96)
Clinical and
laboratory
features
Admission
(pre-CRRT)
Discharge
(post-CRRT)
p Value
Serum creatinine,
mg/dl
(mean±SD)
2.6±1.5 2.6±1.5 0.091
Clinical score
[median (IR)]
5 (3.5 - 7) 1 (0–2.5) b0.001
NT-proBNP
[median (IR)]
16878 (8914–34015) 5114 (1648–12808) b0.001
Patients in NYHA
class I-II, n (%)
4 (6.3) 29 (46.0) b0.001
Patients in NYHA
classes
III–IV, n (%)
59 (93.7) 34 (54.7) b0.001
CRRT-related
complications
Anemia, n (%) 1 (0.8)
Thrombocytopenia,
n (%)
1 (0.8)
Infection, n (%) 1 (0.8)
SCUF, Slow Continuous Ultrafiltration; CVVHDF Continuous Veno-Venous Hemodiafiltration;
CRRT, Continuous Renal ReplacementTherapy.
, Slow Continuous Ultrafiltration; CVVHDF Continuous Veno-Venous Hemodiafil-
tration; CRRT, Conti uous Renal ReplacementTherapy.
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exclusion of alternative causes. CIN prevention with CRRT was
performed with CVVHF in patients with severe chronic renal dysfunc-
tion (GFR ≤30 ml/min/1.73 m2) following Marenzi's protocol [3,4] and
according to recent guidelines on myocardial revascularization [5].
Treatment of CIN with CRRT was performed with CVVHDF in patients
with an increase in creatinine values ≥3 mg/dl associated with oliguria
48–72 hours after contrast medium administration.
AKI was defined as an increase in serum creatinine N0.3 mg/dl
(≥24 μmol/l) or increase ≥150% (N1.5 fold) respect to baseline
associated with a urine output b0.5 ml/kg/h for almost 6 hours [6]. In
this group of patients treatment consisted in CVVHDF.
CRRT was usually performed with a double-lumen catheter placed
in the femoral vein and connected to the PRISMA™ System (HOSPAL-
GAMBRO DASCO, Medolla, Italy) or Aquadex Flex Flow S-100 (CHF
Solutions, Inc., Brooklyn Park, MN 55428, USA) when only SCUF was
indicated. Pre-dilution modality of treatment was preferred to post-
dilution modality for its minor risk of filter clotting. Unfractioned
heparin was used in all patients to prevent filter clotting maintaining
aPTT between 40 and 60 s. In patients at high hemorrhagic risk aPTT
was maintained under 40 s, optimizing blood flow and maintaining
filtration fraction between 10% and 20%.
Anemia was defined according to TIMI minor bleeding classifica-
tion and thrombocytopenia as a platelet reductionN50% respect to
baseline.
Tables 1 and 2 show demographic and clinical characteristics of
patients who underwent CRRT for CHF, CIN prevention/treatment or AKI,
respectively, as well as variations in some parameters determined by
CRRT.
CRRT was initially introduced in clinical practice in intensive care
units for the treatment of AKI associated with critical conditions such
as cardiogenic and septic shock. However, in the last few years the use
of CRRT has been also extended to other conditions such as CHF and
prevention or treatment of CIN, two conditions for which an intensive
environment is not always required. Parallel to this, new technologies
have become available offering devices that are easier to use,
contributing to the diffusion of this treatment also out of the intensive
care units.
These recent advances have led cardiologists to deal increasingly
with this technique and nurses to be specifically trained to manage
CRRT devices.
In agreement with this trend and with new evidences in this field,
since 2005 we progressively introduced CRRT in our clinical practice;
data reported in this letter suggest the safety and feasibility of this
technique also in a CSDU.
In our CHF patients CRRT has been able to improve clinical status and
determine a significant reduction in clinical score, NYHA class and pro-
BNP plasma levels with low rate of complications. In our population
CRRT was also used and resulted as effective in four patients in NYHA
class II at variance with previous studies demonstrating its efficacy in
patients with more advanced NYHA class [1,2].
Moreover, according to the studies by Marenzi et al. [3,4] and to
recent guidelines on myocardial revascularization [5] we used CRRT
also for CIN prevention in patients at high risk for this complication.
Our experience confirmed the efficacy of these techniques since no
patient developed this complication and stable values of creatinine
and higher urinary output after the procedure were observed.
PatientswithAKI fromother causes have been shown tobenefit from
CRRT even though they have, also in our population, a higher mortality,
confirming data from the literature according to which renal dysfunc-
tion is one of the main determinant of in-hospital mortality [7–11].
In conclusion, our data suggest that cardiologists should be able to
manage CRRT even out of an intensive care setting for almost these
three subgroups of patients.
The authors of this manuscript have certified that they comply
with the Principles of Ethical Publishing in the International Journal of
Cardiology [12].
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Contrast transthoracic echocardiography (c-TTE)[1,2] and contrast
transcranial Doppler (c-TCD) [3,4] are widely used for noninvasive
diagnosis of patent foramen ovale (PFO). We thought to evaluate in a
large series of patients the concordance between c-TTE and c-TCD in
right-to-left shunt (RLS) diagnosis and in quantification. From June
2006 to July 2009 RLS was looked for in two hundred thirty two
consecutive patients (160 females, aged 42.6±15.3 years) who
underwent on succession c-TCD and c-TTE at echocardiography
laboratories of San Paolo and Dell'Angelo Hospitals (Milano and
Mestre-Venezia, Italy). All patients gave their informed consent. The
reason for RLS search was migraine in 167 patients (72%), stroke in 23
patients (9.9%), TIA in 29 patients (12.5%) and other causes in 13
patients (5.6%). Contrast TTE and TCD tests were performed using an
agitated saline solution mixed with air [4]. Given that the Valsalva
maneuver (VM) increases the sensitivity of RLS detection all patients
were trained in VM execution. In all cases the study begunwith c-TCD.
In case of no or little microbubbles (MB) detection at the MCA the test
was repeated with VM. Results were classified in a four-level
categorization according to MB appearance in the TCD spectrum as
follows: 0 indicates no occurrence of MB (test negative),1 indicates 1–
10 MB (small shunt), 2 indicatesN10 MB without “curtain” effect
(medium shunt) and finally 3 indicates “curtain” effect, whereas MB
are so numerous that a single MB cannot be discriminated within the
Doppler spectrum (large shunt) [4]. Subsequently patients underwent
c-TTE. Once again results were classified in a four-level categorization
according to MB appearance in the left hear after complete
opacification of the right atrium [2]: 0 indicates no occurrence of
MB (test negative), 1 indicatesb10 MB passed through the PFO (small
shunt), 2 indicates a cloud ofN10 MB documented in the left atrium
(medium shunt) and 3 indicates opacification of the left heart (large
shunt)[5]. Quantitative data were expressed as mean±standard
deviation. Inter observer agreement in the diagnosis and grading of
RLS both on c-TCD and c-TTE was assessed by calculating the Kappa-
statistic. Odds Ratios and 95% Confidence Intervals were calculated.
The concordance between c-TCD and c-TTE scores was estimated
using the Lin's concordance correlation coefficient and the Spearman's
rho rank correlation coefficient. Finally, the optimal trade-off between
sensitivity and specificity of c-TTEwas estimated bymeans of Receiver
Operating Characteristic (ROC) curve analysis. All calculations were
repeated on split subgroups with homogeneous diagnostic question.
Overall, we noticed an excellent interobserver agreement both in c-
TCD RLS scoring (K=0.962, 95%CI 0.93–0.99) and in c-TTE RLS scoring
(K=0.985, 95%CI 0.96–1.00). Subsequently, we compared the c-TCD
and c-TTE RLS gradations. In the overall study population the
concordance correlation coefficient (CCC) between c-TCD and c-TTE
RLS scores was CCC=0.68 (95%CI 0.60–0.74), indicating a moderate
correlation between c-TTE and c-TCD. The Spearman's coefficient of
rank correlation (rho) was 0.68 (95%CI 0.60–0.74) confirming a
moderate correlation between the two diagnostic procedures.
Correlation and concordance between c-TCD and c-TTE RLS gradations
were then analyzed in two subgroups of patients with homogeneous
diagnostic question. The CCC between c-TCD and c-TTE RLS scores was
moderate in patients with migraine (CCC=0.63, 95%CI 0.53–0.71),
and was good in patients referred for cerebrovascular diseases (CVD)
(CCC=0.87, 95%CI 0.79–0.92). The Spearman's coefficient of rank
correlationwas 0.63 (95% CI 0.52 – 0.71) in patientswithmigraine and
0.88 (95%CI 0.80–0.93) in patients with CVD, confirming the good
correlation between the two diagnostic procedures in this subgroup of
patients. The diagnostic performance of c-TTE compared with the
presence of MB on c-TCD is exhibited by the Receiver Operating
Characteristic (ROC) curve (Fig. 1). RLS score≥1 on c-TTE can predict
the presence of MB on c-TCD with the highest trade-off between
sensitivity and specificity both in CVD and in migraine. Nevertheless,
in CVD patients c-TTE had a higher sensitivity (100.0; 95% CI 88.1–
100.0) and specificity (73.9; 95% CI 51.6–89.8) than in patients with
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